6 days Ago By ABMN Staff
Renaissance Technologies LLC raised its holdings in Embecta Corp. ( NASDAQ:EMBC – Free Report ) by 52.7% in the 4th quarter, Holdings Channel.
com reports. The firm owned 68,848 shares of the company’s stock after acquiring an additional 23,748 shares during the period. Renaissance Technologies LLC’s holdings in Embecta were worth $1,422,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in Embecta by 0.
4% in the 4th quarter. Vanguard Group Inc. now owns 7,025,483 shares of the company’s stock valued at $145,076,000 after buying an additional 28,031 shares in the last quarter.
American Century Companies Inc. raised its stake in shares of Embecta by 8.0% during the 4th quarter.
American Century Companies Inc. now owns 3,261,934 shares of the company’s stock valued at $67,359,000 after purchasing an additional 242,668 shares during the period. William Blair Investment Management LLC purchased a new stake in Embecta during the 4th quarter worth about $15,270,000.
Bank of New York Mellon Corp boosted its stake in Embecta by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company’s stock worth $14,155,000 after purchasing an additional 4,769 shares during the period.
Finally, Sei Investments Co. grew its holdings in Embecta by 5.1% during the 4th quarter.
Sei Investments Co. now owns 406,288 shares of the company’s stock valued at $8,390,000 after buying an additional 19,725 shares in the last quarter. Institutional investors own 93.
83% of the company’s stock. Insider Buying and Selling In other Embecta news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $16.
38, for a total transaction of $50,778.00. Following the transaction, the director now directly owns 36,133 shares in the company, valued at $591,858.
54. This trade represents a 7.90 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink . 0.42% of the stock is owned by company insiders.
Wall Street Analyst Weigh In View Our Latest Analysis on Embecta Embecta Stock Performance NASDAQ:EMBC opened at $12.32 on Tuesday. Embecta Corp.
has a 52-week low of $10.00 and a 52-week high of $21.48.
The stock has a fifty day moving average of $12.70 and a 200 day moving average of $15.85.
The firm has a market capitalization of $716.21 million, a price-to-earnings ratio of 12.32, a P/E/G ratio of 0.
78 and a beta of 1.23. Embecta ( NASDAQ:EMBC – Get Free Report ) last issued its quarterly earnings data on Thursday, February 6th.
The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.45 by $0.
20. Embecta had a negative return on equity of 19.22% and a net margin of 5.
25%. Equities analysts forecast that Embecta Corp. will post 2.
85 earnings per share for the current fiscal year. Embecta Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were issued a dividend of $0.
15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.
87%. The ex-dividend date of this dividend was Friday, February 28th. Embecta’s dividend payout ratio is currently 60.
00%. Embecta Profile ( Free Report ) Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes.
Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. Featured Stories Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp.
( NASDAQ:EMBC – Free Report ). Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter .
.
